Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV
作者:
Don Smith,
Jennifer Midgley,
Mhairi Allan,
G. Connolly,
Brian Gazzard,
期刊:
AIDS
(OVID Available online 1991)
卷期:
Volume 5,
issue 11
页码: 1367-1372
ISSN:0269-9370
年代: 1991
出版商: OVID
关键词: Itraconazole;ketoconazole;candidosis
数据来源: OVID
摘要:
To determine the efficacy and toxicity of two systemically active antifungal agents in the treatment of buccal and oesophageal candidiasis 111 HIV-infected patients with microscopically-confirmed candidiasis were randomized to receive either 200 mg itraconazole once a day or 200 mg ketoconazole twice a day for 28 days in a double blind study. After 1 week of treatment, 75 and 82% of the patients on itraconazole and ketoconazole, respectively, had responded clinically. After 4 weeks of treatment, this had risen to 93% in each group. One patient discontinued itraconozole because of toxicity (rash), five patients discontinued ketaconazole (two nausea, two hepatotoxicity and one rash). Despite successful clinical and mycological clearance, 80% patients had a further episode of candidosis within the next 3 months.
点击下载:
PDF
(435KB)
返 回